MaxQ AI’s FDA-cleared and CE Marked Accipio ICH applications for stroke, traumatic brain injury, and head trauma are now available on the Blackford Platform.
 
Developed by MaxQ AI, the Accipio solutions use artificial intelligence (AI) in the assessment of non-contrast head CT images for suspected intracranial hemorrhage (ICH). Accipio Ix is intended for identification and prioritization, while Accpio Ax also includes slice-level annotation.
 
“We’re excited to partner with MaxQ AI and offer the Accipio applications to our customers,” said Ben Panter, CEO, Blackford Analysis. “Since every minute matters for TBI, trauma, and stroke patients, the Accipio algorithms promise to help ensure the right care is delivered faster—improving quality, helping avoid poor patient outcomes, while decreasing costs.”
 
The cost of a missed ICH can be significant, but the economic cost of treating a misdiagnosed patient is nothing compared to the devastation to families and loved ones. Even being able to divert only one patient per year to wellness from stroke care represents a significant saving for a hospital and makes a lifetime of difference to patients and their families.
 
Fully integrated with existing systems, Blackford Platform simplifies the implementation and management of multiple imaging applications and AI algorithms, and reduces load on PACS. New applications can be added to the image-processing platform, reducing implementation time, costs, and long-term maintenance.
 
“Our partnership with Blackford will expand access to our innovative AI-powered ICH solutions for stroke, TBI, and head trauma to radiologists and care providers worldwide, who trust Blackford as a valued partner to deliver quality solutions,” said Gene Saragnese, CEO at MaxQ AI. “We view this as a powerful collaboration that will bridge the technology divide to enable more and more hospitals and healthcare organizations to seamlessly integrate our Accipio platform.”